Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Health Canada/PALYNZIQ

Authorized

STANDARD

PALYNZIQ

Biomarin International Limited🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 6093178b291728a3
Company: Biomarin International Limited
Type: Standard

Approval Details

Approval Id: 6093178b291728a3
Drug Approval Canada Name: PALYNZIQ
Product Name: PALYNZIQ
Status: Marketed
Status Date: 2022-08-26
Original Market Date: 2022-08-26
Din: 02526263
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Prescription , Schedule D
Ahfs: 44:00.00
Atc Original: A16AB19 PEGVALIASE
Atc Name: a 16 ab 19
Aig Number: 0163521001
Company Name: Biomarin International Limited
Company Address: Shanbally, Ringaskiddy, Cork, Ireland, P43R298
Company Detail Path: /organization/biomarin-international-limited

Company Information

Pharmaceutical Company Name: Biomarin International Limited
Country Name: Australia

Active Ingredients

PEGVALIASE

20 MG / ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

6093178b291728a3

Type

Standard

Back to Health Canada Approvals

PALYNZIQ - Health Canada Drug Approval Details